NCT01188668View on ClinicalTrials.gov

Open Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Aripiprazole When Coadministered To Healthy Subjects

PHASE4CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2010

Conditions
PharmacokineticsCytochrome P-450 CYP2D6CYP3A4 Protein, Human
Interventions
DRUG

Aripiprazole

Period 1-Aripiprazole 5mg on study day 1.

DRUG

Aripiprazole + desvenlafaxine succinate sustained release

Period 2-Desvenlafaxine SR 100mg on days 1-19 with coadministration of Aripiprazole 5mg on day 7.

Trial Locations (2)

33126

Pfizer Investigational Site, Miami

33134

Pfizer Investigational Site, Miami

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY